Abstract:Phosphatase and TENsin homolog deleted on chromosome 10 (PTEN) is a tumor suppressor gene located at chromosome 10q23.31, encoding for a 403-amino acid protein that possesses both lipid and protein phosphatase activities. The main function of PTEN is to block the PI3K pathway by dephosphorylating phosphatidylinositol (PI) 3,4,5-triphosphate to PI-4,5-bisphosphate thus counteracting PI3K function. PTEN inactivation is a frequent event in many cancer types and can occur through various genetic alterations including point mutations, large chromosomal deletions, and epigenetic mechanisms. In colorectal cancer (CRC) PTEN is altered through mixed genetic/epigenetic mechanisms (typically: mutations and promoter hypermethylation or 10q23 LOH and promoter hypermethylation), which lead to the biallelic inactivation of the protein in 20-30% of cases. The role of PTEN as a prognostic and predictive factor in CRC has been addressed by relatively few works. This review is focused on the report and on the discussion of the studies investigating these aspects. Overall, at the moment, there are conflicting results and, therefore it has not been clarified whether PTEN might play a prognostic role in CRC. The same is valid also for the predictive role, leading to the fact that PTEN evaluation cannot be used in routinely diagnosis for the early identification of patients who might be addressed to the treatment with EGFR-targeted therapies, at odds with other genetic alterations belonging to EGFR-downstream pathways. The reason of discordant results may be attributable to several issues: (1) the size of the analyzed cohort, (2) patients inclusion criteria, (3) the methods of assessing PTEN alteration. In particular, there are no standardized methods to evaluate this marker, especially for immunohistochemistry, a technique suffering of intra and inter-observer variability due to the semi-quantitative character of such an analysis. In conclusion, much work, especially in large and homogeneous cohorts of cases from different laboratories, has to be done before the establishment of PTEN as prognostic or predictive marker in CRC.

PTEN in Non-Alcoholic Fatty Liver Disease/Non-Alcoholic Steatohepatitis and Cancer

Regulation of the tumor suppressor PTEN by natural anticancer compounds

The complexity of PTEN: mutation, marker and potential target for therapeutic intervention

The regulation of PTEN: Novel insights into functions as cancer biomarkers and therapeutic targets

Decoding PTEN: from biological functions to signaling pathways in tumors

PTEN-protein Expression in Hepatocellular Carcinoma and Its Association with Invasion and Metastasis

PTEN in Colorectal Cancer: Shedding Light on Its Role as Predictor and Target

Epigenetic and Genetic Alterations of PTEN in Hepatocellular Carcinoma

Genetic alterations and expression of PTEN and its relationship with cancer stem cell markers to investigate pathogenesis and to evaluate prognosis in hepatocellular carcinoma.

PTEN deficiency potentiates HBV-associated liver cancer development through augmented GP73/GOLM1

PTEN Deficiency Facilitates Exosome Secretion and Metastasis in Cholangiocarcinoma by Impairing TFEB-mediated Lysosome Biogenesis

EXPRESSION OF PTEN GENE IN HUMAN HEPATOCELLULAR CARCINOMA AND ITS CLINICAL SIGNIFICANCE

Effect of stability of PTEN on hepatocellular carcinoma

PTEN antagonises Tcl1/hnRNPK-mediated G6PD pre-mRNA splicing which contributes to hepatocarcinogenesis

Hepatic HuR protects against the pathogenesis of non-alcoholic fatty liver disease by targeting PTEN

The PTEN–PI3K Axis in Cancer

PTEN/PTENP1: ‘Regulating the regulator of RTK-dependent PI3K/Akt signalling’, new targets for cancer therapy

Functions and Regulation of the PTEN Gene in Colorectal Cancer

The PTEN–PI3K pathway: of feedbacks and cross-talks

Prognostic and Predictive Implications of PTEN in Breast Cancer: Unfulfilled Promises but Intriguing Perspectives

The role of low-molecular-weight protein tyrosine phosphatase (LMW-PTP ACP1) in oncogenesis